Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
232 studies found for:    "thrombotic thrombocytopenic purpura" OR "Purpura, Thrombocytopenic"
Show Display Options
Rank Status Study
21 Not yet recruiting Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Condition: Acquired Thrombotic Thrombocytopenic Purpura
Intervention: Biological: caplacizumab
22 Recruiting A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Hetrombopag Olamine
23 Completed Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Conditions: Chronic Idiopathic Thrombocytopenic Purpura;   Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Placebo;   Drug: AKR-501 Tablets
24 Terminated Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: BI 655064
25 Completed
Has Results
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Conditions: Chronic Idiopathic Thrombocytopenic Purpura;   Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: SB-497115-GR 12.5mg;   Drug: SB-497115-GR 25mg;   Drug: SB-497115-GR 12.5mg matching placebo;   Drug: SB-497115-GR 50 mg
26 Completed An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
Conditions: Purpura, Thrombocytopenic, Idiopathic;   Immune Thrombocytopenic Purpura
Intervention:
27 Completed
Has Results
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Conditions: Idiopathic Thrombocytopenic Purpura;   Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Eltrombopag oral tablets
28 Withdrawn Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura
Condition: Purpura, Thrombotic Thrombocytopenic
Interventions: Drug: Octaplas infusion and placebo (group 1);   Drug: Octaplas infusion and placebo (group 2)
29 Unknown  Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
Condition: Autoimmune Thrombocytopenic Purpura
Intervention: Drug: Doxil
30 Terminated Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Biological: GMA161
31 Completed A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Fostamatinib Disodium 100mg;   Drug: Placebo;   Drug: Fostamatinib Disodium 150mg
32 Completed Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution
33 Recruiting IdeS in Asymptomatic Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
Condition: Purpura, Thrombotic Thrombocytopenic
Intervention: Biological: HMed-IdeS
34 Completed Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: rituximab
35 Completed Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Condition: Thrombocytopenic Purpura
Intervention: Drug: AMG 531
36 Completed Efficacy and Safety of IVIG-L in ITP Patients
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: IVIG-L
37 Completed Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura
Condition: Idiopathic Thrombocytopenic Purpura
Intervention:
38 Completed
Has Results
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
39 Completed Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: LGD-4665;   Drug: Placebo
40 Completed SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)
Condition: Purpura, Thrombocytopaenic, Idiopathic
Intervention: Drug: SB497115

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.